AURORA
Research type
Research Study
Full title
AURORA: Atezolizumab in patients with urinary tract squamous cell carcinoma: a single arm, open label, multicentre, phase II clinical trial
IRAS ID
1004493
Contact name
Rachael Meering
Contact email
Sponsor organisation
University Hospital Southampton NHS Foundation Trust
Eudract number
2021-004995-32
Clinicaltrials.gov Identifier
Research summary
The AURORA trial is designed for patients who have been diagnosed with urinary tract squamous cell carcinoma (UTSCC). This disease has few treatment options and poor outcomes for patients. \nAtezolizumab is currently an experimental treatment for UTSCC. This is because it has never been tested specifically in this uncommon cancer type before. However, we have some preliminary biological data from urinary tract SCC patient tumour samples that suggests that they might be expected to respond to immunotherapy treatment. We know, from the use of atezolizumab to treat other cancers including more common types of urinary tract cancer, that it is generally more tolerable and with fewer side-effects than chemotherapy. The trial is aiming to recruit a maximum of 36 patients in total.
REC name
London - Chelsea Research Ethics Committee
REC reference
22/LO/0272
Date of REC Opinion
24 May 2022
REC opinion
Further Information Favourable Opinion